FDA Inspection 1209368 — New York Blood Center Enterprises

New York Blood Center Enterprises — FEI 2473015

The FDA completed an inspection of New York Blood Center Enterprises on July 6, 2023 in Rye, NY. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 6 citations were issued during this inspection. Product area: Biologics.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
July 6, 2023
Fiscal Year
2023
Product Type
Biologics
Project Area
Blood and Blood Products
Location
Rye, NY (United States)

Citations

IDCFRDescription
15521 CFR 606.160(b)Required records
6721 CFR 606.65(e)Following manufacturer's instructions
7621 CFR 606.100(b)Establish, maintain and follow manufacturing SOPs
907821 CFR 600.12(a)Maintenance - tracing
908921 CFR 600.14(c)When to report
9821 CFR 606.100(c)Thorough investigations